ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

"Government health care dollars are precious and must be used without favor in order to achieve the highest possible health ...

Pennsylvania will receive $1.28 million as part of a $202 million national settlement with Gilead Sciences Inc., after the company was accused of orchestrating an illegal ...

Massachusetts AG Campbell secures $1.6 million for the state's Medicaid in a settlement with Gilead over illegal kickbacks ...

Pennsylvania looks to be getting millions from a biopharma company for violating anti-kickback laws. Gilead Sciences, Inc.

A company was ordered to pay hundreds of thousands of dollars to D.C. to settle claims that it engaged in an illegal kickback scheme.

GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...

Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

South Africa has accepted an offer of just over $29 million (about R520 million) from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year anti-HIV jab, lenacapavir, that research ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...